PROPANC BIOPHARMA, INC. Debt Instrument, Fee Amount
PROPANC BIOPHARMA, INC. (PPCB) had Debt Instrument, Fee Amount of $2.34 thousand as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFeeAmount · last filed 2026-07-17
- 2026-03-31: Debt Instrument, Fee Amount $2.34K.
- 2025-12-31: Debt Instrument, Fee Amount $2.34K.
- 2025-09-30: Debt Instrument, Fee Amount $1.41K.
- 2025-06-30: Debt Instrument, Fee Amount $0.00; Debt Instrument, Fee Amount as first filed $3.77K.
| Period end | Debt Instrument, Fee Amount | Debt Instrument, Fee Amount as first filed |
|---|---|---|
| 2026-03-31 | $2.34K S-1 · filed 2026-07-17 | |
| 2025-12-31 | $2.34K S-1 · filed 2026-04-10 | |
| 2025-09-30 | $1.41K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $0.00 S-1 · filed 2026-07-17 | $3.77K 10-K · filed 2025-09-29 |
| 2025-03-31 | $3.77K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $2.83K 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $798.00 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $3.83K S-1 · filed 2026-07-17 | |
| 2024-03-31 | $2.24K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.60K 10-Q · filed 2024-02-20 | |
| 2023-09-30 | $1.44K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $1.84K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |